Histopathologic characteristics of therapy‐associated cutaneous neoplasms with vemurafenib, a selective <scp>BRAF</scp> kinase inhibitor, used in the treatment of melanoma

Abstract

We describe the histopathologic findings of skin lesions potentially associated with vemurafenib. Additional investigation is necessary to further elucidate cutaneous neoplasms associated with vemurafenib; however, frequent dermatologic evaluation is warranted in all patients receiving BRAF inhibitors.